Bristol-Myers Squibb Q2 2024 Adj EPS $2.07 Beats $1.63 Estimate, Sales $12.201B Beat $11.547B Estimate
Portfolio Pulse from Benzinga Newsdesk
Bristol-Myers Squibb reported Q2 2024 adjusted EPS of $2.07, beating the estimate of $1.63. Sales were $12.201 billion, surpassing the expected $11.547 billion.
July 26, 2024 | 11:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol-Myers Squibb's Q2 2024 earnings and sales both exceeded analyst expectations, with EPS at $2.07 versus the $1.63 estimate and sales at $12.201 billion versus the $11.547 billion estimate.
The significant beat on both EPS and sales is likely to positively impact Bristol-Myers Squibb's stock price in the short term as it indicates strong financial performance and operational efficiency.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100